Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Atomoxetine (Primary)
- Indications Memory disorders
- Focus Therapeutic Use
- Acronyms RETAIN-MS
- 13 Jun 2018 Status changed from recruiting to completed.
- 18 Apr 2018 Planned End Date changed from 13 Mar 2018 to 15 Jun 2018.
- 18 Apr 2018 Planned primary completion date changed from 13 Mar 2018 to 15 Jun 2018.